Natera, Inc. - Common Stock (NQ:NTRA)

229.11 -0.87 (-0.38%)

Streaming Delayed Price Updated: 3:27 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Volume	337,447
Open	229.98
Bid (Size)	229.00 (200)
Ask (Size)	229.22 (200)
Prev. Close	229.98
Today's Range	228.92 - 231.91
52wk Range	125.38 - 246.90
Shares Outstanding	137,533,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Via MarketMinute

3 Growth Stocks with Explosive Upside

December 28, 2025

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who...

Via StockStory

Performance

YTD	+42.7%	+42.7%
1 Month	-2.2%	-2.2%
3 Month	+42.3%	+42.3%
6 Month	+42.6%	+42.6%
1 Year	+44.5%	+44.5%

More News

3 Reasons We’re Fans of Natera (NTRA)

December 23, 2025

Via StockStory

3 Market-Beating Stocks Worth Your Attention

December 22, 2025

Via StockStory

Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

From Natera, Inc.

Via Business Wire

Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer

December 18, 2025

From Natera, Inc.

Via Business Wire

I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer

December 16, 2025

From Natera, Inc.

Via Business Wire

Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer

December 12, 2025

From Natera, Inc.

Via Business Wire

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post‑Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2‑ Breast Cancer

December 10, 2025

From Natera, Inc.

Via Business Wire

Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting

December 09, 2025

From Natera, Inc.

Via Business Wire

Natera Acquires Foresight Diagnostics

December 05, 2025

From Natera, Inc.

Via Business Wire

New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

December 03, 2025

From Natera, Inc.

Via Business Wire

Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera™ at the San Antonio Breast Cancer Symposium

December 02, 2025

From Natera, Inc.

Via Business Wire

3 Cash-Producing Stocks with Solid Fundamentals

December 01, 2025

Via StockStory

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Via The Motley Fool

Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know

November 24, 2025

Via StockStory

Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks

November 23, 2025

Via StockStory

Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know

November 21, 2025

Via StockStory

Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3

November 19, 2025

Via StockStory

Employees Volunteer Over 1,500 Hours During Natera’s Annual Volunteer Month

November 19, 2025

From Natera, Inc.

Via Business Wire

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Via Benzinga

Natera Integrates with Flatiron Health’s OncoEMR® Platform

November 12, 2025

From Natera, Inc.

Via Business Wire

1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds

November 11, 2025

Via StockStory

2 Surging Stocks with Impressive Fundamentals and 1 We Question

November 10, 2025

Via StockStory

Natera (NTRA) Q3 2025 Earnings Call Transcript ↗

November 09, 2025

Via The Motley Fool

Frequently Asked Questions

Is Natera, Inc. - Common Stock publicly traded?

Yes, Natera, Inc. - Common Stock is publicly traded.

What exchange does Natera, Inc. - Common Stock trade on?

Natera, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Natera, Inc. - Common Stock?

The ticker symbol for Natera, Inc. - Common Stock is NTRA on the Nasdaq Stock Market

What is the current price of Natera, Inc. - Common Stock?

The current price of Natera, Inc. - Common Stock is 229.11

When was Natera, Inc. - Common Stock last traded?

The last trade of Natera, Inc. - Common Stock was at 12/31/25 03:27 PM ET

What is the market capitalization of Natera, Inc. - Common Stock?

The market capitalization of Natera, Inc. - Common Stock is 31.51B

How many shares of Natera, Inc. - Common Stock are outstanding?

Natera, Inc. - Common Stock has 32B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.